IOL Chemicals & Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9oa7tdb5j2yxsx8fwzwz6qkl.pdf

Key Takeaways


Performance Drivers

Mahajan: "We have sufficient cash flow operating and in hand cash with the company as of now."

Capital Projects: The Next Growth Cycle

Singh: "The benefit is there that we have visibility of the realizations and the profits as well. Also, this opens us the opportunities for entering the CDMO business for the chemicals also."

Ibuprofen: Pricing, Capacity & Strategy

Singh: "I think considering there's so much dynamism in the current situation, forecasting 2, 3 years, prices of the Ibuprofen from there is risky for me."

Regulatory & Market Access Milestones


Order Book & Demand Visibility


Margins & Cost Structure

Singh: "I think the sustainable — I think we should rather than being aspirational, we should talk more on the sustainable EBITDA number. So around 15% to 17% is a sustainable number, and we should target that."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growth25% plus revenue growth, surpassing previous ~₹2,700 Cr guidanceFY27 full year
FY27 EBITDA margin14–15% EBITDA marginFY27 full year
H2 FY27 performanceQ3 and Q4 expected to have more or less same performance as H1Q3 and Q4 FY27
Ibuprofen expansion commissioning12,000 to 18,000 MTPA; optimum utilization in FY28–29FY28
CDMO facility commercialization150 crore tablets/year; validation batches already with anchor customersFY28
Specialty chemicals plant startBatches expected to start in November; gradual ramp-upNovember (Q3 FY27)
Ibuprofen pricingExpected to remain at same levelNext 2–3 quarters
Sustainable blended EBITDA15–17% targetMedium-term (no date)
Capex for FY27₹250 crores planned; ~half spent in H1, remainder in H2FY27
Peak short-term borrowing~₹200 crores; no additional borrowing expectedAs of 30 Sep 2026
Other expenses (power, freight)Expected to decreaseQ3 and Q4 FY27

Key Metrics

MetricQ2 FY27
Revenue from operations₹795 cr, ~40% YoY and high single-digit QoQ
H1 FY27 revenue₹1,551 cr, ~39% YoY
EBITDA~₹115 cr, ~80% YoY (vs ₹64 cr in Q2 FY26)
EBITDA margin14.4%, improved 321 bps YoY (vs 11.2% in Q2 FY26)
H1 FY27 EBITDA~₹227 cr, ~70% YoY; margin 14.5% (vs 11.8% in H1 FY26)
Profit after tax~₹65 cr, ~117% YoY (vs ₹30 cr in Q2 FY26)
H1 FY27 PAT~₹130 cr, more than doubled YoY (vs ₹64 cr in H1 FY26)
Non-ibuprofen pharma revenue growth~70% YoY, contributing 45% of pharma revenue (vs 38% in Q2 FY26)
Chemicals business EBIT contribution~7% of overall EBIT (vs ~1% in Q2 FY26)
Exports contribution~28% of H1 FY27 revenue
Ibuprofen capacity utilization~90% to 95% for last 3–4 quarters
FY27 revenue growth guidance25% plus
FY27 EBITDA margin guidance14% to 15%
Chemicals segment growth38% in Q2
Planned capex for FY27₹250 cr, ~half spent in H1, remainder in H2
Short-term borrowing₹200 cr as of 30 Sep 2026, stated as peak working capital for the rest of the year